Name: KLOW
Brand: Amino Club
SKU: KLOW - 80MG
Availability: InStock
Rating: 4.9 (142 reviews)

KLOW | 99%+ Pure Peptide | Amino Club | Amino Club

What Makes KLOW Different?

The Science, Simplified

Four Pathways, One Formula

KLOW builds upon the GLOW formula by adding KPV, a potent anti-inflammatory tripeptide derived from α-MSH. BPC-157 promotes angiogenesis through VEGF pathways, TB-500 enhances cell migration via actin regulation, GHK-Cu stimulates collagen synthesis and gene expression, and KPV inhibits NF-κB activation to reduce inflammation. Together, they address tissue repair and inflammation at multiple biological levels.

BPCPrimary

VEGF Pathway

Vascular Endothelial Growth Factor (BPC-157)

Promotes blood vessel formation
Enhances tissue granulation
Modulates nitric oxide signaling

TB4Primary

Actin Regulation

Thymosin Beta-4 Pathway (TB-500)

Increases cell migration
Supports cytoskeletal remodeling
Reduces fibrotic scarring

CuPrimary

Collagen & ECM

Copper Peptide Signaling (GHK-Cu)

Stimulates type I & III collagen
Modulates 4,000+ genes
Delivers copper to cells

KPVPrimary

NF-κB Inhibition

Anti-Inflammatory Signaling (KPV)

Inhibits NF-κB activation
Reduces pro-inflammatory cytokines
PepT1-mediated cellular uptake

Multi-Pathway Regeneration Research

Why Four Peptides Work Together

Enhanced Regeneration with Anti-Inflammatory Control

Each peptide in KLOW addresses a different phase of tissue repair while KPV provides critical inflammatory control. BPC-157 initiates vascular support and blood flow to damaged areas. TB-500 mobilizes repair cells through enhanced migration. GHK-Cu provides the collagen framework and gene activation for structural rebuilding. KPV inhibits NF-κB to create an optimal anti-inflammatory environment for healing.

Multi-phase healing: Research suggests combining regenerative peptides with anti-inflammatory agents may produce superior tissue repair outcomes by preventing chronic inflammation from impeding the healing cascade.

GLOW (BPC+TB+Cu)3 regenerative pathways

KPV aloneNF-κB inhibition

KLOW (All 4)Complete regeneration + inflammation control

KPV: The Fourth Component

Alpha-MSH Derived Anti-Inflammatory

KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH) and retains most of α-MSH's anti-inflammatory activity. Unlike melanocortin peptides, KPV works through PepT1-mediated cellular uptake rather than melanocortin receptors, making it uniquely effective for direct intracellular NF-κB pathway modulation.

Key finding: KPV exhibits anti-inflammatory effects even stronger than full-length α-MSH in some studies, with a favorable safety profile due to its small size and natural origin.

α-MSH (13 AA)MCR-dependent effects

KPV (3 AA)PepT1-mediated, MCR-independent

Research Applications

Areas studied in preclinical models

Gut

Health

KPV shows particular promise for intestinal inflammation research, with PepT1-mediated uptake enhanced during IBD conditions

Dalmasso et al. 2008

Skin

Regeneration

GHK-Cu promotes collagen synthesis while BPC-157, TB-500, and KPV support epithelial repair and reduce inflammation

Pickart & Margolina 2018

Tissue

Repair

TB-500 facilitates actin remodeling; BPC-157 promotes tendon fibroblast viability; GHK-Cu supports vascular stabilization; KPV controls inflammation

Chi et al. 2017

Anti-

Inflammatory

Four peptides with distinct anti-inflammatory mechanisms: KPV inhibits NF-κB; BPC-157 modulates NO; TB-500 affects macrophages; GHK-Cu downregulates TNF-α

Luger et al. 2007

Anti-Inflammatory

KPV: NF-κB Pathway Modulation

KPV is the C-terminal tripeptide of α-MSH that retains powerful anti-inflammatory activity. It inhibits NF-κB activation at nanomolar concentrations, reduces pro-inflammatory cytokine secretion (IL-8, TNF-α), and shortens the duration of inflammatory signaling. Unlike full-length α-MSH, KPV works through PepT1 transport rather than melanocortin receptors.

NF-κB inhibitionConfirmed at nanomolar levels

IL-8 reductionDose-dependent decrease

Transport mechanismPepT1-mediated

IBD expression↑ PepT1 enhances uptake

Gastroenterology 2008

Gastrointestinal

Intestinal Inflammation Research

KLOW combines BPC-157's established gastrointestinal protective effects with KPV's targeted anti-inflammatory action. In colitis models, oral KPV reduced inflammation markers, body weight loss, and tissue damage. The upregulation of PepT1 during IBD conditions actually enhances KPV therapeutic targeting.

BPC-157 GI protection

+90%

KPV colitis reduction

+85%

TB-500 epithelial repair

+75%

Dalmasso et al. 2008

Dermatological

Skin & Aesthetic Research

The KLOW blend is studied in preclinical skin models for effects on dermal remodeling, wound closure, barrier restoration, and inflammatory skin conditions. GHK-Cu promotes collagen synthesis while BPC-157 and TB-500 support epithelial repair. KPV adds anti-inflammatory effects relevant to conditions like dermatitis.

Collagen synthesis↑ 70% (GHK-Cu)

Gene modulation4,000+ genes

Inflammation controlKPV NF-κB inhibition

Skin conditions studiedContact dermatitis, wounds

GHK-Cu Skin Research

Musculoskeletal

Muscle & Tendon Repair

In musculoskeletal research, KLOW addresses both tissue regeneration and the inflammatory component of injuries. Each peptide contributes unique repair mechanisms, while KPV prevents chronic inflammation that can impair healing outcomes.

TB-500 cell migration

+85%

BPC-157 angiogenesis

+80%

GHK-Cu vascularization

+75%

KPV inflammation control

+85%

Seiwerth et al. 2018

Frequently Asked Questions

Common questions about KLOW research

KLOW is a quad-peptide blend containing BPC-157 (a 15-amino acid gastric peptide), TB-500 (a 43-amino acid thymosin beta-4 fragment), GHK-Cu (a copper tripeptide), and KPV (a 3-amino acid α-MSH fragment). Each peptide targets different but complementary mechanisms, with KPV adding potent anti-inflammatory activity through NF-κB inhibition.

GLOW contains BPC-157, TB-500, and GHK-Cu, focusing on angiogenesis, cell migration, and collagen synthesis. KLOW adds KPV, which brings powerful NF-κB inhibition and anti-inflammatory activity. This fourth component is particularly relevant for inflammatory conditions and extends the blend's research applications to include gut inflammation and inflammatory skin conditions.

KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH). Unlike full-length α-MSH which works through melanocortin receptors, KPV is transported into cells via PepT1 transporters. Once inside cells, it inhibits NF-κB activation and reduces pro-inflammatory cytokine production. Importantly, PepT1 expression is upregulated during inflammatory bowel disease, making KPV particularly effective in inflamed gut tissue.

KPV's anti-inflammatory effects are NOT melanocortin receptor-mediated. Instead, KPV enters cells through the PepT1 di/tripeptide transporter, which is normally expressed in the small intestine and induced in the colon during IBD. This allows KPV to directly access intracellular inflammatory pathways at nanomolar concentrations, inhibiting NF-κB activation and reducing the duration of inflammatory signaling.

KPV has been studied in models of inflammatory bowel disease (DSS- and TNBS-induced colitis), contact dermatitis, cutaneous vasculitis, asthma, rheumatoid arthritis, and ocular inflammation. Research shows that oral KPV significantly reduces inflammation, body weight loss, and tissue damage in colitis models. Studies in Gastroenterology (2007) demonstrated that KPV's anti-inflammatory effect works through PepT1-mediated uptake and subsequent NF-κB/MAPK pathway inhibition.

No. All four peptides are research compounds. BPC-157 and TB-500 are investigational peptides with no FDA approval and are banned by WADA. GHK-Cu is used in cosmetic formulations but is not approved as a therapeutic. KPV is a naturally occurring peptide fragment used for research purposes. KLOW is intended for laboratory and preclinical research applications only.

Yes, research indicates KPV is effective via oral administration. Because KPV is transported by PepT1 (a di/tripeptide transporter expressed in the intestine), it can be absorbed intact from the gut. Studies in Gastroenterology showed that oral KPV reduced inflammation in colitis models. The other three components (BPC-157, TB-500, GHK-Cu) are typically administered via injection in research protocols.

Lyophilized (powder) form should be stored at -20°C for long-term stability. Once reconstituted, store at 2-8°C (refrigerated) and use within 7 days. Protect from light and avoid repeated freeze-thaw cycles. Each component has slightly different stability profiles, so follow manufacturer guidelines for specific formulations.

KLOW

Frequently Researched Together

GHK-Cu

Four Pathways, One Formula

VEGF Pathway

Actin Regulation

Collagen & ECM

NF-κB Inhibition

Enhanced Regeneration with Anti-Inflammatory Control

Alpha-MSH Derived Anti-Inflammatory

Key Metrics by Component

Individual Peptide Performance

KPV: NF-κB Pathway Modulation

Intestinal Inflammation Research

Skin & Aesthetic Research

Muscle & Tendon Repair

Injection site reactions

No systemic toxicity

KPV safety profile

Preclinical Safety Summary

Important Considerations

💡Researcher Notes

What Is In KLOW?

Alpha-MSH C-Terminal Fragment

Stability Information

Where Each Stands

What is KLOW and what does it contain?

How does KLOW differ from GLOW?

What is KPV and how does it work?

What makes KPV's mechanism unique?

What research has been done on KPV?

Is KLOW approved for human use?

Can KPV be taken orally?

How should KLOW be stored?

PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation

α-MSH Related Peptides: A New Class of Anti-Inflammatory and Immunomodulating Drugs

Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis

Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data

Thymosin Beta 4 and Cardiac Repair

BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing

BPC-157 Upregulates Growth Hormone Receptor Expression

Combined Peptide Research Literature

Individual Peptide Research Literature

⚠️Important Research Notice

All the research peptides you need, with the peace of mind and research community at your fingertips.

Stay Updated with Amino Club

Frequently Researched Together

GHK-Cu

Researcher Notes